On this page

Clobetasol propionate

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Clobetasol Propionate
Generic name
Clobetasol propionate
Dosage form
Gel
Route
Topical
Marketing category
ANDA · ANDA
Labeler
Bryant Ranch Prepack
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
1
NDC product codes
7
Packages
15
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Clobetasol Propionate .5 mg/g 861490 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Gel
Route of administration
Topical
Presentations
22

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
075027
Application type
ANDA · Abbreviated New Drug Application
Approval date
October 31, 1997
Sponsor
PADAGIS US
Products on application
1
Submissions recorded
5
Products approved under application 075027.
Product Trade name Form Strength Ingredient Status TE Flags
075027-001 CLOBETASOL PROPIONATE GEL CLOBETASOL PROPIONATE Prescription AB RS

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
Yes

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 075027.
Type No. Action Status Date Review
Supplement 5 Labeling Approved November 28, 2007 —
Supplement 4 Labeling Approved December 20, 2000 —
Supplement 3 Manufacturing (CMC) Approved December 20, 2000 —
Supplement 2 Labeling Approved July 24, 2000 —
Original application 1 Approved October 31, 1997 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20251008). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20251008 HUMAN PRESCRIPTION DRUG · 20230717

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE Clobetasol Propionate Gel, 0.05% is a super-high potency corticosteroid formulation indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 g/week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. Use in pediatric patients under 12 years of age is not recommended.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION Apply a thin layer of Clobetasol Propionate Gel, 0.05% to the affected skin areas twice daily and rub in gently and completely (see INDICATIONS AND USAGE ). Clobetasol Propionate Gel, 0.05% is a super-high potency topical corticosteroid; therefore, treatment should be limited to 2 consecutive weeks and amounts greater than 50 g/week should not be used. As with other highly active corticosteroids, therapy should be discontinued when control has been achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. Clobetasol Propionate Gel, 0.05% should not be used with occlusive dressings.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS Clobetasol Propionate Gel, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS In a controlled trial with clobetasol propionate gel, 0.05%, the only reported adverse reaction that was considered to be drug related was a report of burning sensation (1.8% of treated patients). In larger controlled clinical trials with other clobetasol propionate formulations, the most frequently reported adverse reactions have included burning, stinging, irritation, pruritus, erythema, folliculitis, cracking and fissuring of the skin, numbness of fingers, skin atrophy, and telangiectasia (all less than 2%). Cushing’s syndrome has been reported in infants and adults as a result of prolonged use of topical clobetasol propionate formulations. The following additional local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with super-high potency corticosteroids such as Clobetasol Propionate Gel, 0.05%. These reactions are listed in approximate decreasing order of occurrence: dryness, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, irritation, striae, and miliaria.

Description

openFDA Drug Labeling

DESCRIPTION Clobetasol Propionate Gel, 0.05% contains the active compound clobetasol propionate, a synthetic corticosteroid, for topical dermatologic use. Clobetasol, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. Chemically, clobetasol propionate is (11ß,16ß)-21-chloro-9-fluoro-11-hydroxy-16- methyl-17-(1-oxopropoxy)-pregna-1,4-diene-3,20-dione, and it has the following structural formula: Clobetasol propionate has the empirical formula C 25 H 32 ClFO 5 and a molecular weight of 467. It is a white to cream-colored crystalline powder insoluble in water. Clobetasol Propionate Gel, 0.05% contains clobetasol propionate 0.5 mg/g in a base of carbomer homopolymer type B, propylene glycol, purified water, and sodium hydroxide. structural_formula

OVERDOSAGE Topically applied Clobetasol Propionate Gel, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Clobetasol Propionate Gel, 0.05% is available as follows: 15 g tube (NDC 72162-1438-2) 30 g tube (NDC 72162-1438-3) 60 g tube (NDC 72162-1438-6) Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504

Adverse event reports

Source: openFDA FAERS
10,472
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: CLOBETASOL PROPIONATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
63629-8637-1 63629-8637 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8637-1) / 15 g in 1 TUBE July 30, 2008
63629-8638-1 63629-8638 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8638-1) / 30 g in 1 TUBE November 11, 2008
63629-8639-1 63629-8639 Bryant Ranch Prepack 1 TUBE in 1 CARTON (63629-8639-1) / 60 g in 1 TUBE July 31, 2008
72162-1438-2 72162-1438 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1438-2) / 15 g in 1 TUBE August 16, 2023
72162-1438-3 72162-1438 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1438-3) / 30 g in 1 TUBE August 16, 2023
72162-1438-6 72162-1438 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-1438-6) / 60 g in 1 TUBE August 16, 2023
0168-0293-15 0168-0293 E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. 15 g in 1 TUBE (0168-0293-15) February 15, 2000
0168-0293-30 0168-0293 E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. 30 g in 1 TUBE (0168-0293-30) February 15, 2000
0168-0293-60 0168-0293 E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. 60 g in 1 TUBE (0168-0293-60) February 15, 2000
45802-925-14 45802-925 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-925-14) / 15 g in 1 TUBE July 30, 2008
45802-925-94 45802-925 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-925-94) / 30 g in 1 TUBE November 11, 2008
45802-925-96 45802-925 Padagis Israel Pharmaceuticals Ltd 1 TUBE in 1 CARTON (45802-925-96) / 60 g in 1 TUBE July 31, 2008
51672-1294-1 51672-1294 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1294-1) / 15 g in 1 TUBE May 28, 1999
51672-1294-2 51672-1294 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1294-2) / 30 g in 1 TUBE May 28, 1999
51672-1294-3 51672-1294 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1294-3) / 60 g in 1 TUBE May 28, 1999
63629-8637 63629-8637 Bryant Ranch Prepack — July 30, 2008
63629-8638 63629-8638 Bryant Ranch Prepack — July 30, 2008
63629-8639 63629-8639 Bryant Ranch Prepack — July 30, 2008
72162-1438 72162-1438 Bryant Ranch Prepack — July 30, 2008
0168-0293 0168-0293 E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. — February 15, 2000
45802-925 45802-925 Padagis Israel Pharmaceuticals Ltd — July 30, 2008
51672-1294 51672-1294 Sun Pharmaceutical Industries, Inc. — May 28, 1999

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.